title: High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
abstract: The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m(2) q12h, days 1-3; mitoxantrone 10 mg/m(2), days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 x 10(9)/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.
authors.affiliation: Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany. richard.schlenk@medizin.uni-ulm.de
authors.forename: R F
authors.initials: RF
authors.lastname: Schlenk
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: F
authors.initials: F
authors.lastname: Hartmann
authors.forename: A
authors.initials: A
authors.lastname: Glasmacher
authors.forename: J T
authors.initials: JT
authors.lastname: Fischer
authors.forename: F
authors.initials: F
authors.lastname: del Valle y Fuentes
authors.forename: K
authors.initials: K
authors.lastname: Götze
authors.forename: H
authors.initials: H
authors.lastname: Pralle
authors.forename: C
authors.initials: C
authors.lastname: Nerl
authors.forename: H
authors.initials: H
authors.lastname: Salwender
authors.forename: W
authors.initials: W
authors.lastname: Grimminger
authors.forename: A
authors.initials: A
authors.lastname: Petzer
authors.forename: M
authors.initials: M
authors.lastname: Hensel
authors.forename: A
authors.initials: A
authors.lastname: Benner
authors.forename: L
authors.initials: L
authors.lastname: Zick
authors.forename: K
authors.initials: K
authors.lastname: Döhner
authors.forename: S
authors.initials: S
authors.lastname: Fröhling
authors.forename: H
authors.initials: H
authors.lastname: Döhner
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage*; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D011518:Proto-Oncogene Proteins; D003561:Cytarabine; D014212:Tretinoin; D008942:Mitoxantrone; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; D015255:Idarubicin